In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Gender-correlated differences in a population with hypertrophic cardiomyopathy. A portuguese multicenter study.

Session Up-to-date research on left ventricular function

Speaker Liliana Reis

Event : EuroEcho 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Rapid Fire Abstracts

Authors : L Reis (Coimbra,PT), J Bispo (Faro,PT), B Marmelo (Viseu,PT), M Oliveira (Guimaraes,PT), R Santos (Penafiel,PT), K Domingues (Santarem,PT), R Faria (Guimaraes,PT), A Marreios (Faro,PT), N Marques (Faro,PT)

L Reis1 , J Bispo2 , B Marmelo3 , M Oliveira4 , R Santos5 , K Domingues6 , R Faria4 , A Marreios7 , N Marques2 , 1University Hospitals of Coimbra - Coimbra - Portugal , 2Faro Hospital - Faro - Portugal , 3Hospital Sao Teotonio - Viseu - Portugal , 4Hospital Guimaraes - Guimaraes - Portugal , 5Hospital Centre do Tamega e Sousa - Penafiel - Portugal , 6Hospital of Santarem - Santarem - Portugal , 7Faro Hospital, Algarve biomedical center, Statistics - Faro - Portugal ,

On behalf: Sunshine

European Heart Journal Supplements ( 2017 ) 18 ( Supplement 3 ), iii4

Introduction: Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease characterized by extreme heterogeneity in clinical expression. This disorder is caused by cardiac sarcomeric protein genes mutations and is most frequently transmitted as an autosomal dominant trait. Since gender plays an important role in the clinical expression and prognosis of various cardiovascular diseases. Little is known regarding the impact of gender in this disease. We aim to assess gender-related differences in a population with HCM.

Methods: Portuguese retrospective study, comprising 567 patients diagnosed with HMC in 12 hospitals. There were evaluated clinical, genetic, electrocardiographic, echocardiographic and magnetic resonance parameters. Mean follow-up duration was 8.0±6.1 years, no difference in length between male (M) and female (F) was found. The clinical endpoints of interest were dysrhythmic events, stroke, cardiovascular mortality and all cause mortality.

Results: The main characteristics by gender, at presentation, are listed in table 1.
At initial evaluation, F patients were older and more symptomatic than M patients. No gender differences were observed in genetic, electrocardiographic and echocardiographic parameters. Regarding CMR parameters, late enhancement was more prevalent in M patients (51% vs 67%, p=0.04).
Although F were more symptomatic, there were no differences in progression to chronic heart failure, medical treatment, implantation of ICD, dysrhythmic events, stroke and all cause mortality. HCM-related mortality and risk of sudden death were similar in men and women. After adjusting for age, NYHA functional class and late enhancement, no differences were observed between genders.

Conclusion: As previously reported on HCM, women are older, more symptomatic and have worse prognosis. But unlike the other studies, in our population, the female gender was not associated with a worse prognosis.



Male patients

Female patients

P value

Number, N (%)


333 (59%)

234 (41%)

Age (years)


59 ± 15

67 ± 15


Type of MCH, N (%)

- Assymmetric

- Symmetric

- Apical




209 (63%)

43 (13%)

42 (13%)

135 (58%)

29 (12%)

41 (18%)




LVOT, N (%)


76 (23%)

64 (27%)


NYHA class>II, N (%)


158 (47%)

166 (71%)


Late enhancement, N (%)


128 (67%)

69 (51%)


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are